- Home
- GRI vs SLXN Comparison
GRI vs SLXN Comparison
Compare GRI & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRI
- SLXN
- Stock Information
- Founded
- GRI 2018
- SLXN 2008
- Country
- GRI United States
- SLXN Israel
- Employees
- GRI N/A
- SLXN N/A
- Industry
- GRI Biotechnology: Pharmaceutical Preparations
- SLXN
- Sector
- GRI Health Care
- SLXN
- Exchange
- GRI Nasdaq
- SLXN NYSE
- Market Cap
- GRI 3.0M
- SLXN 3.0M
- IPO Year
- GRI N/A
- SLXN N/A
- Fundamental
- Price
- GRI $0.77
- SLXN $0.21
- Analyst Decision
- GRI Strong Buy
- SLXN Strong Buy
- Analyst Count
- GRI 1
- SLXN 1
- Target Price
- GRI $12.00
- SLXN $1.00
- AVG Volume (30 Days)
- GRI 9.9M
- SLXN 1.5M
- Earning Date
- GRI 11-14-2024
- SLXN 11-14-2024
- Dividend Yield
- GRI N/A
- SLXN N/A
- EPS Growth
- GRI N/A
- SLXN N/A
- EPS
- GRI N/A
- SLXN N/A
- Revenue
- GRI N/A
- SLXN N/A
- Revenue This Year
- GRI N/A
- SLXN N/A
- Revenue Next Year
- GRI N/A
- SLXN N/A
- P/E Ratio
- GRI N/A
- SLXN N/A
- Revenue Growth
- GRI N/A
- SLXN N/A
- 52 Week Low
- GRI $0.30
- SLXN $0.21
- 52 Week High
- GRI $106.29
- SLXN $13.56
- Technical
- Relative Strength Index (RSI)
- GRI 49.32
- SLXN N/A
- Support Level
- GRI $0.79
- SLXN N/A
- Resistance Level
- GRI $1.00
- SLXN N/A
- Average True Range (ATR)
- GRI 0.17
- SLXN 0.00
- MACD
- GRI -0.02
- SLXN 0.00
- Stochastic Oscillator
- GRI 24.95
- SLXN 0.00
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.